Supplementary Material

Supplementary table 1: Clinically diagnosed type 1 diabetes baseline characteristics of whole cohort by age group. Data are mean (SD) or n (%). Missing variables have been treated as absent. * Body mass index (BMI) was age adjusted using WHO (2007) reference data (26)

Mean (95% CI)		All N=1814	<18 N=702	18-30 N=524	>30 N=588
Age at diagnosis (years)		25 (14)	12 (3)	24 (3)	42 (10)
Sex	Male	1088 (60%)	400 (57%)	322 (61%)	366 (62%)
	Female	726 (40%)	302 (43%)	202 (39%)	222 (38%)
Diabetes duration (weeks)		11 (7)	13 (7)	10 (7)	11 (7)
Baseline HbA1c (mmol/mol)		87 (33)	77 (31)	92 (33)	94 (32)
BMI (kg/m2)*		24 (5)	23 (4)	24 (5)	26 (5)
≥1 antibody positive		1536 (85%)	642 (91%)	457 (87%)	437 (74%)
GADA		1268 (70%)	463 (66%)	392 (75%)	413 (70%)
IA2A		1034 (57%)	517 (74%)	299 (57%)	218 (37%)
ZNT8A		906 (50%)	449 (64%)	261 (50%)	196 (33%)
Diabetic Ketoacidosis		737 (41%)	277 (39%)	221 (42%)	239 (41%)
Hospitalised at admission		1345 (74%)	656 (93%)	346 (66%)	343 (58%)
Weight loss at diagnosis		1535 (85%)	576 (82%)	438 (84%)	521 (89%)
Polyuria or polydipsia		1715 (95%)	677 (96%)	490 (94%)	548 (93%)
Another autoimmune disease		122 (7%)	26 (4%)	23 (4%)	73 (12%)

Supplementary table 2: Clinical features of clinically diagnosed type 1 diabetes diagnosed <18 years of age by islet autoantibody status. Data are mean (SD) or n (%). Missing variables have been treated as absent. * Body mass index (BMI) was age adjusted using WHO (2007) reference data (26)

		Diagnosed <18 years of age, ≥1 Antibody positive n=642	Diagnosed <18 years of age, All antibodies negative n=60	p
At diagnosis				
Age at diagnosis (years)		12 (3)	11 (4)	<0.01
Sex	Male	364 (57%)	36 (60%)	0.62
	Female	278 (43%)	24 (40%)	0.62
Diabetic Ketoacidosis		259 (40%)	18 (30%)	0.12
Weight loss		523 (81%)	53 (88%)	0.19
Polyuria or polydipsia		619 (97%)	58 (97%)	0.92
Hospitalised at admission		599 (93%)	57 (95%)	0.61
At Recruitment				
Diabetes duration (weeks)		13 (7)	13 (7)	0.90
HbA1c (mmol/mol)		78 (31)	75 (28)	0.63
BMI (kg/m2)*		23 (4)	23 (3)	0.68
T1DGRS		0.277 (0.026)	0.274 (0.034)	0.37
On concurrent oral hypoglycaemic agent		0 (0%)	0 (0%)	n/a
Another autoimmune disease		24 (4%)	2 (3%)	0.87

Supplementary table 3: Clinical features of clinically diagnosed type 1 diabetes diagnosed 18-30 years of age by islet autoantibody status. Data are mean (SD) or n (%). Missing variables have been treated as absent.

		Diagnosed 18-30 years of age, ≥1 Antibody positive n=457	Diagnosed 18-30 years of age, All antibodies negative n=67	p
At diagnosis				
Age (years)		24 (3)	24 (3)	0.06
Sex	Male	276 (60%)	46 (69%)	0.19
	Female	181 (40%)	21 (31%)	0.19
Diabetic Ketoacidosis		194 (42%)	27 (40%)	0.74
Weight loss		385 (84%)	53 (79%)	0.29
Polyuria or polydipsia		430 (94%)	60 (90%)	0.16
Hospitalised at admission		304 (67%)	42(63%)	0.54
At recruitment				
Diabetes duration (weeks)		10 (7)	10 (7)	0.90
HbA1c (mmol/mol)		91 (33)	98 (37)	0.12
BMI (kg/m2)		24 (5)	26 (7)	0.01
T1DGRS		0.271 (0.026)	0.253 (0.039)	<0.0001
On concurrent oral hypoglycaemic agent		6 (1%)	9 (13%)	<0.0001
Another autoimmune disease		21 (5%)	2 (3%)	0.55

Supplementary table 4: Pattern of islet autoantibody types in genetically defined type 1 diabetes by age group. Data are n (%, 95% CI)

	Age <18 years n=698	**Age 18-30 years n=494**	**Age >30 years n=471**	p
Triple islet autoantibody negative	56 (8%, 6-10)	37 (7%, 5-10)	34 (7%, 5-10)	0.9
Single GADA Positive	58 (8%, 6-10)	106 (21%, 18-25)	163 (35%, 30-39)	<0.0001
Single IA2A Positive	48 (7%, 5-9)	18 (4%, 2-5)	8 (2%, 1-3)	<0.001
Single ZNT8A Positive	19 (3%, 2-4)	10 (2%, 1-3)	4 (1%, 0-2)	0.08
GADA & IA2A Positive	87 (12%, 10-15)	72 (15%, 11-18)	70 (15%, 12-18)	0.4
GADA & ZNT8A Positive	48 (7%, 5-9)	42 (8%, 6-11)	52 (11%, 8-14)	0.04
IA2A & ZNT8A Positive	112 (16%, 13-19)	37 (7%, 5-10)	12 (3%, 1-4)	<0.0001
GADA, IA2A & ZNT8A Positive	270 (39%, 35-42)	172 (35%, 31-39)	128 (27%, 23-31)	<0.001

Supplementary figure 1: Flow diagram showing cohort selection and case exclusion



Supplementary figure 2: Distribution of type 1 diabetes genetic risk score (T1DGRS) by number of positive islet autoantibodies in three age groups.



Figure 3: Flowchart showing results of mono-genetic analysis on islet autoantibody negative cases